Found 1383 clinical trials
HER2-PREDICT: Translational Study of Tumor Samples From DS8201-A-U301 and DS8201-A-U302 Trials.
Patients who will participate, are participating or have participated in Daichi Sankyo INC sponsored Ds8201-A-U301 and Ds8201-A-U302 trials will be asked to participate to HER2-PREDICT study offering them a new informed consent. In order to identify mRNA ERBB2 levels, we will evaluate by gene expression tumor samples from these patients.
- 0 views
- 19 Feb, 2024
- 1 location
A Study of the Safety and Tolerability of GTX-102 in Children With Angelman Syndrome
Approximately 20 patients (male and female) 4 and 17 years of age with a genetically confirmed diagnosis of full maternal UBE3A gene deletion (within 15q11.2-q13 region) will be enrolled.
- 0 views
- 19 Feb, 2024
- 4 locations
A Study of DCC-2618 (Ripretinib) Evaluating Efficacy Safety and Pharmacokinetics In Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
The primary objective of this trial is to evaluate the progress free survival (PFS) of DCC-2618 in patients with advanced gastrointestinal stromal tumors who have progressed with prior anticancer therapies based on independent radiologic review.This study will enroll approximately 35 subjects in up to 10 sites in China mainland, and …
- 0 views
- 19 Feb, 2024
- 9 locations
Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy
The purpose of this additional part of the study is to test whether the study drug, nivolumab, is a safe treatment that will prevent participants' primary central nervous system lymphoma (PCNSL) from growing again (recurrence). Participants will be people with PCNSL who continue to have cell free tumor DNA (cfDNA) …
- 0 views
- 19 Feb, 2024
- 7 locations
Phase 2 Trial in Multiple Brain Metastases Outcomes With HA-SIB-WBRT
Patients who are fit, have multiple brain metastases (5-25 lesions) and reasonable life expectancy (>6 months) will be recruited from NCCS over 2 years. Patients will be followed up the over the following year with imaging, toxicity data, quality of life, activities of daily living and cognitive measurements at set …
- 0 views
- 19 Feb, 2024
- 1 location
change - Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic Sclerosis (TOP-N53-02)
Participants will receive one or two treatments with the placebo or different strengths of TOP-N53. The higher strength of the drug will only be given to participants after the lower strength was found to be safe.Participants will visit the clinic up to 8 times within a maximum of 31 days. …
- 0 views
- 13 Jun, 2025
- 3 locations
Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic Sclerosis (TOP-N53-02)
Participants will receive one or two treatments with the placebo or different strengths of TOP-N53. The higher strength of the drug will only be given to participants after the lower strength was found to be safe.Participants will visit the clinic up to 8 times within a maximum of 31 days. …
- 0 views
- 28 May, 2025
- 1 location
UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy
Assessment of interactions between race and vascular risk factors, brain amyloid levels measured with [C-11]PiB-PET, and cognitive status will be the primary outcome of this imaging study.
- 0 views
- 19 Feb, 2024
- 1 location
Effects of Pau d' Arco in Primary Dysmenorrhea
A single arm, open-label trial evaluating safety and tolerability of encapsulated Tabebuia avellanedae in 12 generally healthy women aged 18-45 with primary dysmenorrhea (PDM). This will be the first study evaluating the safety and tolerability of Tabebuia avellanedae in PDM. We also aim to collect proof-of-concept mechanistic data supporting the …
- 0 views
- 19 Feb, 2024
- 1 location
FemBloc Permanent Contraception Trial
The purpose of this study is to evaluate if changes to the FemBloc Permanent Contraceptive System are effective in increasing reliance (the ability of a woman to be able to depend on FemBloc for contraception once the treatment and confirmation test have been performed), and decreasing pregnancy rate.
- 0 views
- 19 Feb, 2024
- 3 locations